Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Non-Current Deffered Revenue (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Non-Current Deffered Revenue for 12 consecutive years, with $5.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Non-Current Deffered Revenue fell 83.5% year-over-year to $5.5 million, compared with a TTM value of $5.5 million through Sep 2025, down 83.5%, and an annual FY2024 reading of $26.9 million, down 66.44% over the prior year.
  • Non-Current Deffered Revenue was $5.5 million for Q3 2025 at CytomX Therapeutics, down from $10.2 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $267.8 million in Q1 2021 and bottomed at $5.5 million in Q3 2025.
  • Average Non-Current Deffered Revenue over 5 years is $130.7 million, with a median of $140.9 million recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue rose 25.52% in 2021, then plummeted 83.5% in 2025.
  • Year by year, Non-Current Deffered Revenue stood at $243.9 million in 2021, then fell by 26.19% to $180.1 million in 2022, then crashed by 55.54% to $80.0 million in 2023, then crashed by 66.44% to $26.9 million in 2024, then crashed by 79.39% to $5.5 million in 2025.
  • Business Quant data shows Non-Current Deffered Revenue for CTMX at $5.5 million in Q3 2025, $10.2 million in Q2 2025, and $16.2 million in Q1 2025.